Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
Pediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. …
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
NCT ID: NCT06712875
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed o…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT07346157
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
Sponsor: SignPath Pharma, Inc.
NCT ID: NCT05768919
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
EARLY Phase 1 Recruiting Academic/Other
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study wil…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT04655404
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
EARLY Phase 1 Recruiting Academic/Other
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with che…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06333899
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT04732065
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.
Sponsor: University of Florida
NCT ID: NCT06514898
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethyla…
Sponsor: University of Florida
NCT ID: NCT04573140
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from …
Sponsor: Children's National Research Institute
NCT ID: NCT06193759
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05839379
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Recruiting Academic/Other
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed wi…
Sponsor: Children's National Research Institute
NCT ID: NCT05697874
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07129317
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss …
Sponsor: Georgetown University
NCT ID: NCT07105358
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia